Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or

DrugDrug NameDrug Description
DrugDrug NameTargetType
DrugDrug NamePhaseStatusCount
DB06769Bendamustine2Completed1
DB06650Ofatumumab2Completed1